ACADIA Pharmaceuticals Inc (ACAD)
18.94
-0.09 (-0.47%)
USD |
NASDAQ |
Feb 01, 10:32
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 3.067B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -15.38% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.996 |
| Price to Book Value | 7.205 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 77.18% |
News
Headline
Wire
Time (ET)
MT Newswires
01/31 09:26
Yahoo
01/09 09:00
MT Newswires
01/03 13:07
Yahoo
01/03 11:58
MT Newswires
01/03 10:25
Yahoo
12/21 16:05
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/28/2023* | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/28/2023* | -- | Results | Q4 2022 | -- | -0.25 | -- | |
| 11/02/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/02/2022 | -- | Results | Q3 2022 | -0.17 | -0.20 | 13.02% | |
| 08/08/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/08/2022 | -- | Results | Q2 2022 | -0.21 | -0.25 | 14.95% | |
| 05/04/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/04/2022 | -- | Results | Q1 2022 | -0.70 | -0.60 | -17.25% |
*Estimated Date/Time
Earnings
Profile
Edit
| Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. |
| URL | https://www.acadia-pharm.com |
| Investor Relations URL | https://ir.acadia.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 28, 2023 (est.) |
| Last Earnings Release | Nov. 02, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 31, 2023.
Fundamentals
| Revenue (TTM) | 511.50M |
| Total Expenses (TTM) | 733.69M |
| Net Income (TTM) | -217.34M |
| Total Assets (Quarterly) | 602.49M |
| Total Liabilities (Quarterly) | 176.80M |
| Shareholders Equity (Quarterly) | 425.69M |
| Cash from Operations (TTM) | -113.30M |
| Cash from Investing (TTM) | 162.54M |
| Cash from Financing (TTM) | 10.95M |
Ratings
Profile
Edit
| Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. |
| URL | https://www.acadia-pharm.com |
| Investor Relations URL | https://ir.acadia.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 28, 2023 (est.) |
| Last Earnings Release | Nov. 02, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| F000016ZD9 | 509.00 USD | 5.09% |
| IBRN | 256340.0 USD | 4.73% |
| SMHCLX | 425.00 USD | 4.25% |
| F00001ENUS | 361.00 USD | 3.61% |
| PBE | 8.561M USD | 3.25% |
| SMHCMX | 302.00 USD | 3.02% |
| BBP | 355276.0 USD | 1.97% |
| SBIO | 2.010M USD | 1.72% |
| XBI | 94.99M USD | 1.15% |
| LABU | 8.201M USD | 0.73% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ACAD Tweets |